Stock RVX RESVERLOGIX CORP.
Add to a list
To use this feature you must be a member
Log inSign up

All News Resverlogix Corp.

Equities

RVX

CA76128M1086

Market Closed - Toronto S.E.
Other stock markets
 20:49:10 28/06/2024 BST 		5-day change 1st Jan Change
0.05 CAD -.--% Intraday chart for Resverlogix Corp. -.--% -28.57%
05-15 Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-01 Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Resverlogix Announces Updated Annual and Special Meeting of Shareholders
NE
Resverlogix : Financial Statement Q1 2024
PU
Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges
NE
Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Resverlogix Announces Change to Its Board of Directors
NE
Resverlogix Corp. Announces Resignation of Shawn Lu from the Board of Directors
CI
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits
NE
Resverlogix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Resverlogix Corp. Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
CI
Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
NE
RESVERLOGIX ANNOUNCES A FAVORABLE OUTLOOK BASED ON NEW CARDIOVASCULAR DISEASE TREATMENT GUIDELINES FOR PATIENTS WITH TYPE 2 DIABETES
AQ
Resverlogix : Financial Statement Q2 2023
PU
Resverlogix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
RESVERLOGIX ANNOUNCES WARRANT REPRICING AND ONE-YEAR EXTENSION
AQ
Transcript : Resverlogix Corp. - Shareholder/Analyst Call
RESVERLOGIX ANNOUNCES NEW INSIGHTS INTO THE MECHANISM OF APABETALONE'S CARDIOPROTECTIVE BENEFIT IN CHRONIC KIDNEY DISEASE PATIENTS
AQ
Resverlogix : Financial Statement Q1 2023
PU
Resverlogix : MD&A Q1 2023
PU
Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RVX Stock
  4. News Resverlogix Corp.